Protein C News and Research

RSS

Gene variant predicts lymphoma treatment response

German researchers have identified a gene variant that significantly influences the outcome of methotrexate therapy for primary central nervous system lymphoma.

31 Oct 2012

Biomarker discovery offers hope for lung cancer blood test

Blood levels of a variant form of the nuclear matrix protein Ciz1 are significantly higher in individuals with early- and late-stage lung cancer than in lung cancer-free individuals, researchers report.

31 Oct 2012

Pins made of single atoms to fight cancer

Answers are often elusive in the fight against cancer, and Rice University chemist Zachary Ball is hoping to pin one down -- with pins made of single atoms. The work, which aims to create a drug that's effective against an "undruggable" protein, is one of the first 50 proposals funded under the National Cancer Institute's (NCI) Provocative Questions Project.

31 Oct 2012

Researchers discover how tamoxifen-resistant breast-cancer cells grow and proliferate

A study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has discovered how tamoxifen-resistant breast-cancer cells grow and proliferate.

31 Oct 2012

High vitamin D levels associated with protection against bladder cancer

High levels of vitamin D are associated with protection against bladder cancer, according to a multidisciplinary study coordinated by molecular biologists and epidemiologists from the Spanish National Cancer Research Centre (CNIO), the conclusions of which are being published today in the Journal of National Cancer Institute (JNCI) .

31 Oct 2012

Blocking RSK protein activity could improve treatment of skin cancers

Blocking the action of a particular protein in our skin could improve the treatment of skin cancers, according to a study published in Oncogene yesterday by Philippe Roux, a researcher at the University of Montreal's Institute for Research in Immunology and Cancer (IRIC).

31 Oct 2012

Eliminating bacteria's DNA, boosting antimicrobial proteins may help prevent recurrent ear infections

Eliminating bacteria's DNA and boosting antimicrobial proteins that already exist may help prevent middle ear infections from reoccurring. These are the findings from a Nationwide Children's Hospital study that examined how an immune defense protein common in the middle ear interacts with a structure meant to protect a colony of bacteria.

31 Oct 2012

Unique bond between SAP102 and GluN2B enables learning and memory

Two proteins have a unique bond that enables brain receptors essential to learning and memory to not only get and stay where they're needed, but to be hauled off when they aren't, researchers say.

31 Oct 2012

Researchers show how ingesting too much silver can cause argyria

Researchers from Brown University have shown for the first time how ingesting too much silver can cause argyria, a rare condition in which patients' skin turns a striking shade of grayish blue.

31 Oct 2012

Preeclampsia risk higher for women with Lupus

New research reports that women with systemic lupus erythematosus (SLE) have a two-fold increase in risk of preeclampsia—a dangerous condition in which pregnant women develop high blood pressure (hypertension) and protein in their urine (proteinuria) after 20 weeks of gestation

30 Oct 2012

Complix to accelerate development of CPABs against intracellular disease targets

Complix announces that it has been awarded a €1.9 million grant (approximately USD$2.4 million) from the Flanders government through IWT (Agency for Innovation by Science and Technology in Flanders).

30 Oct 2012

STAT3 transcription factor remains in the axon of nerve cells to help prevent neurodegeneration

A study in The Journal of Cell Biology shows how a transcription factor called STAT3 remains in the axon of nerve cells to help prevent neurodegeneration. The findings could pave the way for future drug therapies to slow nerve damage in patients with neurodegenerative diseases.

30 Oct 2012

IPSCs may be a viable source of patient-specific articular cartilage tissue

A team of Duke Medicine researchers has engineered cartilage from induced pluripotent stem cells that were successfully grown and sorted for use in tissue repair and studies into cartilage injury and osteoarthritis.

30 Oct 2012

Researchers decode software instructions that drive 3 different forms of acute lymphoblastic leukemia

30 Oct 2012

Oxidative stress occurs in genetic models of alpha-1-antitrypsin deficiency

A team of researchers under the direction of Dr. Jeffrey Teckman in the Department of Pediatrics at St. Louis University, have demonstrated that oxidative stress occurs in a genetic model of alpha-1-antitrypsin deficiency.

30 Oct 2012

TTP488 slows cognitive decline in patients with mild to moderate Alzheimer's

A novel, orally administered drug candidate, TTP488, has demonstrated clinical evidence of slowing of cognitive decline over 18 months of therapy in patients with mild to moderate Alzheimer's disease.

30 Oct 2012

Positive results from Celldex’s CDX-1401 Phase 1 study on solid tumors

Celldex Therapeutics, Inc. today announced positive results demonstrating promising clinical effects in a Phase 1 study of CDX-1401 in solid tumors in combination with the toll-like receptor (TLR) agonists resiquimod and/or Poly ICLC.

30 Oct 2012

Scientists discover β2-syntrophin protein as new prognosis marker for prostate cancer

Scientists have discovered a molecular 'tell' in laboratory experiments that could help doctors determine the severity of a patient's prostate cancer.

30 Oct 2012

BioRx added to Zemaira distribution network

BioRx, a national specialty pharmacy and infusion services provider, has been added to the limited distribution network for Zemaira [alpha-1 proteinase inhibitor (human)]. Zemaira is indicated for chronic augmentation and maintenance therapy in individuals with alpha1-antitrypsin (AAT) deficiency and clinical evidence of emphysema.

30 Oct 2012

Scientists decode epigenetic programming of three virulent forms of acute lymphoblastic leukemia

A team of national and international researchers, led by Weill Cornell Medical College scientists, have decoded the key "software" instructions that drive three of the most virulent forms of acute lymphoblastic leukemia (ALL). They discovered ALL's "software" is encoded with epigenetic marks, chemical modifications of DNA and surrounding proteins, allowing the research team to identify new potential biomarkers and therapeutic targets.

29 Oct 2012